Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study

Authors: Péter Torzsa, Raghavendra Devadiga, Monica Tafalla

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Pertussis (whooping cough) is well known to be underreported, particularly among adults, who can act as an infectious reservoir, potentially putting susceptible newborns at risk of serious illness. The purpose of this study was to estimate the seroprevalence of pertussis in adults in Hungary.

Methods

This epidemiological, cross-sectional study was conducted in adults in five general practitioners’ practices in Hungary. Serum anti-pertussis toxin immunoglobulin G (anti-PT IgG) antibody levels were analyzed using enzyme-linked immunosorbent assay. Sera were classified following manufacturer’s instructions as: strongly indicative of current/recent infection (≥1.5 optical density [OD] units); indicative of current/recent infection (≥1.0 OD units); seropositive (>0.3 OD units); or seronegative (≤0.3 OD units). Logistic regression was performed to describe the associations between seroprevalence and various characteristics.

Results

Between 24th April 2014 and 24th April 2015, 1999 adults (60.6% female; mean age 47.4 ± 17.7 years) were included in the analysis. A total of 14.8% were seropositive for anti-PT IgG, 1.1% had a level indicative of current/recent infection, and 0.1% had a level strongly indicative of current/recent infection. Logistic regression showed significant relationships between increased rates of seropositivity and: age ≥60 years (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.39–2.80; p = .0002) or 18–29 years (OR, 1.67; 95% CI, 1.13–2.46; p = .0094) vs. 45–59 years; former smoker (OR, 1.46; 95% CI, 1.08–1.97; p = .014) or current smoker (OR, 1.38; 95% CI, 1.01–1.89; p = .045) vs. never smoker; and male (OR, 1.30; 95% CI, 1.01–1.68; p = .041) vs. female. Also, between increased rates of probable current/recent infection and current smoker (OR, 7.50; 95% CI, 2.32–24.31; p = .0008) or former smoker (OR, 4.07; 95% CI, 1.21–13.64; p = .023) vs. never smoker.

Conclusions

Approximately 85% of the adults studied were seronegative and therefore susceptible to pertussis infection. Approximately 1% had anti-PT IgG levels indicative of current/recent pertussis infection, which could potentially be transmitted to susceptible young infants. Vaccination of adults is a key way to indirectly protect infants.

Trial registration

Clinical Trials.gov NCT02014519. Prospectively registered 12 December 2013.
Literature
3.
go back to reference Joo I. Epidemiology of pertussis in Hungary. Dev Biol Stand. 1991;73:357–9.PubMed Joo I. Epidemiology of pertussis in Hungary. Dev Biol Stand. 1991;73:357–9.PubMed
4.
go back to reference Heininger U, Andre P, Chlibek R, Kristufkova Z, Kutsar K, Mangarov A, et al. Comparative epidemiologic characteristics of Pertussis in 10 central and eastern European countries, 2000–2013. PLoS One. 2016;11:e0155949.CrossRefPubMedPubMedCentral Heininger U, Andre P, Chlibek R, Kristufkova Z, Kutsar K, Mangarov A, et al. Comparative epidemiologic characteristics of Pertussis in 10 central and eastern European countries, 2000–2013. PLoS One. 2016;11:e0155949.CrossRefPubMedPubMedCentral
7.
go back to reference Esposito S, Principi N, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG). Immunization against pertussis in adolescents and adults. Clin Microbiol Infect. 2016;22(Suppl 5):S89-S95. Esposito S, Principi N, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG). Immunization against pertussis in adolescents and adults. Clin Microbiol Infect. 2016;22(Suppl 5):S89-S95.
8.
go back to reference Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–61.CrossRefPubMed Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–61.CrossRefPubMed
9.
go back to reference Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011;11:557–70.CrossRefPubMed Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011;11:557–70.CrossRefPubMed
10.
go back to reference World Health Organization (WHO). Pertussis vaccines: WHO position paper, August 2015 – Recommendations. Vaccine. 2016;34:1423–5.CrossRef World Health Organization (WHO). Pertussis vaccines: WHO position paper, August 2015 – Recommendations. Vaccine. 2016;34:1423–5.CrossRef
16.
go back to reference Barkoff AM, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathog Dis. 2015;73:ftv050. Barkoff AM, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathog Dis. 2015;73:ftv050.
17.
go back to reference Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Tropical Med Int Health. 2016;21:1086–98.CrossRef Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Tropical Med Int Health. 2016;21:1086–98.CrossRef
18.
go back to reference Taranger J, Trollfors B, Lagergård T, Sundh V, Bryla DA, Schneerson R, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181:1010–3.CrossRefPubMed Taranger J, Trollfors B, Lagergård T, Sundh V, Bryla DA, Schneerson R, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181:1010–3.CrossRefPubMed
19.
go back to reference Euro Diagnostica. Instruction: PERTUSSCAN PT IgG: ELISA for detection of IgG against Bordatella pertussis toxin (PT) in serum. Malmö: Euro Diagnostica; 2013. p. 120. Document No.: E-23-0207-02 Euro Diagnostica. Instruction: PERTUSSCAN PT IgG: ELISA for detection of IgG against Bordatella pertussis toxin (PT) in serum. Malmö: Euro Diagnostica; 2013. p. 120. Document No.: E-23-0207-02
20.
go back to reference Rendi-Wagner P, Tobias J, Moerman L, Goren S, Bassal R, Green M, et al. The seroepidemiology of Bordetella pertussis in Israel – estimate of incidence of infection. Vaccine. 2010;28:3285–90.CrossRefPubMed Rendi-Wagner P, Tobias J, Moerman L, Goren S, Bassal R, Green M, et al. The seroepidemiology of Bordetella pertussis in Israel – estimate of incidence of infection. Vaccine. 2010;28:3285–90.CrossRefPubMed
21.
go back to reference Pavlopoulou ID, Syriopoulou V, Daikos GL, Fourlani H, Tzivaras A, Petychakis D, et al. Pertussis seroprevalence in different age groups in Greece. Scand J Infect Dis. 2007;39:14–8.CrossRefPubMed Pavlopoulou ID, Syriopoulou V, Daikos GL, Fourlani H, Tzivaras A, Petychakis D, et al. Pertussis seroprevalence in different age groups in Greece. Scand J Infect Dis. 2007;39:14–8.CrossRefPubMed
22.
go back to reference Scott S, van der Sande M, Faye-Joof T, Mendy M, Sanneh B, Barry Jallow F, et al. Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates. Pediatr Infect Dis J. 2015;34:333–8.CrossRefPubMedPubMedCentral Scott S, van der Sande M, Faye-Joof T, Mendy M, Sanneh B, Barry Jallow F, et al. Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates. Pediatr Infect Dis J. 2015;34:333–8.CrossRefPubMedPubMedCentral
23.
go back to reference Lee SY, Han SB, Bae EY, Kim JH, Kang JH, Park YJ, et al. Pertussis seroprevalence in korean adolescents and adults using anti-pertussis toxin immunoglobulin G. J Korean Med Sci. 2014;29:652–6.CrossRefPubMedPubMedCentral Lee SY, Han SB, Bae EY, Kim JH, Kang JH, Park YJ, et al. Pertussis seroprevalence in korean adolescents and adults using anti-pertussis toxin immunoglobulin G. J Korean Med Sci. 2014;29:652–6.CrossRefPubMedPubMedCentral
24.
go back to reference Conde-Glez C, Lazcano-Ponce E, Rojas R, DeAntonio R, Romano-Mazzotti L, Cervantes Y, et al. Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study. Epidemiol Infect. 2014;142:706–13.CrossRefPubMed Conde-Glez C, Lazcano-Ponce E, Rojas R, DeAntonio R, Romano-Mazzotti L, Cervantes Y, et al. Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study. Epidemiol Infect. 2014;142:706–13.CrossRefPubMed
25.
go back to reference Wanlapakorn N, Ngaovithunvong V, Thongmee T, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Seroprevalence of antibodies to Pertussis toxin among different age groups in Thailand after 37 years of universal whole-cell Pertussis vaccination. PLoS One. 2016;11:e0148338.CrossRefPubMedPubMedCentral Wanlapakorn N, Ngaovithunvong V, Thongmee T, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Seroprevalence of antibodies to Pertussis toxin among different age groups in Thailand after 37 years of universal whole-cell Pertussis vaccination. PLoS One. 2016;11:e0148338.CrossRefPubMedPubMedCentral
26.
go back to reference González-Escalada A, García-García L, Viguera-Ester P, Marín-García P, García J, Gil-de-Miguel A, et al. Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain. Hum Vaccin Immunother. 2013;9:1918–25.CrossRefPubMedPubMedCentral González-Escalada A, García-García L, Viguera-Ester P, Marín-García P, García J, Gil-de-Miguel A, et al. Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain. Hum Vaccin Immunother. 2013;9:1918–25.CrossRefPubMedPubMedCentral
27.
go back to reference Palazzo R, Carollo M, Fedele G, Rizzo C, Rota MC, Giammanco A, et al. Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012–2013). J Med Microbiol. 2016:[Epub ahead of print]. Palazzo R, Carollo M, Fedele G, Rizzo C, Rota MC, Giammanco A, et al. Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012–2013). J Med Microbiol. 2016:[Epub ahead of print].
28.
go back to reference Wirsing von König CH. Pertussis diagnostics: overview and impact of immunization. Expert Rev Vaccines. 2014;13:1167–74.CrossRefPubMed Wirsing von König CH. Pertussis diagnostics: overview and impact of immunization. Expert Rev Vaccines. 2014;13:1167–74.CrossRefPubMed
30.
go back to reference Caboré RN, Piérard D, Huygen K. A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. Vaccines (Basel). 2016;4:E16. Caboré RN, Piérard D, Huygen K. A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. Vaccines (Basel). 2016;4:E16.
31.
go back to reference de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR, Mollema L, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One. 2010;5:e14183.CrossRefPubMedPubMedCentral de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR, Mollema L, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One. 2010;5:e14183.CrossRefPubMedPubMedCentral
32.
go back to reference Huygen K, Rodeghiero C, Govaerts D, Leroux-Roels I, Melin P, Reynders M, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012. Epidemiol Infect. 2014;142:724–8.CrossRefPubMed Huygen K, Rodeghiero C, Govaerts D, Leroux-Roels I, Melin P, Reynders M, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012. Epidemiol Infect. 2014;142:724–8.CrossRefPubMed
33.
go back to reference Launay O, Toneatti C, Bernede C, Njamkepo E, Petitprez K, Leblond A, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin. 2009;5:341–6.CrossRefPubMed Launay O, Toneatti C, Bernede C, Njamkepo E, Petitprez K, Leblond A, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin. 2009;5:341–6.CrossRefPubMed
34.
go back to reference Rønn PF, Dalby T, Simonsen J, Jørgensen CS, Linneberg A, Krogfelt KA. Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark. Epidemiol Infect. 2014;142:729–37.CrossRefPubMed Rønn PF, Dalby T, Simonsen J, Jørgensen CS, Linneberg A, Krogfelt KA. Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark. Epidemiol Infect. 2014;142:729–37.CrossRefPubMed
35.
go back to reference Xu Y, Wang L, Xu J, Wang X, Wei C, Luo P, et al. Seroprevalence of pertussis in China: need to improve vaccination strategies. Hum Vaccin Immunother. 2014;10:192–8.CrossRefPubMed Xu Y, Wang L, Xu J, Wang X, Wei C, Luo P, et al. Seroprevalence of pertussis in China: need to improve vaccination strategies. Hum Vaccin Immunother. 2014;10:192–8.CrossRefPubMed
36.
go back to reference Chen Z, Zhang J, Cao L, Zhang N, Zhu J, Ping G, et al. Seroprevalence of pertussis among adults in China where whole cell vaccines have been used for 50 years. J Infect. 2016;73:38–44. Chen Z, Zhang J, Cao L, Zhang N, Zhu J, Ping G, et al. Seroprevalence of pertussis among adults in China where whole cell vaccines have been used for 50 years. J Infect. 2016;73:38–44.
37.
go back to reference de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006;53:106–13. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006;53:106–13.
38.
go back to reference Carcione D, Regan AK, Tracey L, Mak DB, Gibbs R, Dowse GK, et al. The impact of parental postpartum pertussis vaccination on infection in infants: a population-based study of cocooning in Western Australia. Vaccine. 2015;33:5654–61. Carcione D, Regan AK, Tracey L, Mak DB, Gibbs R, Dowse GK, et al. The impact of parental postpartum pertussis vaccination on infection in infants: a population-based study of cocooning in Western Australia. Vaccine. 2015;33:5654–61.
39.
go back to reference Healy CM, Rench MA, Wootton SH, Castagnini LA. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J. 2015;34:22–6.CrossRefPubMed Healy CM, Rench MA, Wootton SH, Castagnini LA. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J. 2015;34:22–6.CrossRefPubMed
40.
go back to reference Safadi MA. Control of pertussis in infants: time has finally come? Expert Rev Vaccines. 2015;14:781–3.CrossRefPubMed Safadi MA. Control of pertussis in infants: time has finally come? Expert Rev Vaccines. 2015;14:781–3.CrossRefPubMed
41.
go back to reference McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015;135:331–43.CrossRefPubMed McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015;135:331–43.CrossRefPubMed
42.
go back to reference Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular partussis vaccine in young adults. Clin Infect Dis. 2010;51:656–62.CrossRefPubMed Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular partussis vaccine in young adults. Clin Infect Dis. 2010;51:656–62.CrossRefPubMed
43.
go back to reference Ridda I, Yin JK, King C, Raina MacIntyre C, McIntyre P. The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly. Vaccine. 2012;30:6745–52.CrossRefPubMed Ridda I, Yin JK, King C, Raina MacIntyre C, McIntyre P. The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly. Vaccine. 2012;30:6745–52.CrossRefPubMed
44.
go back to reference El Ahmer OR, Essery SD, Saadi AT, Raza MW, Ogilvie MM, Weir DM, et al. The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. FEMS Immunol Med Microbiol. 1999;23:27–36.CrossRefPubMed El Ahmer OR, Essery SD, Saadi AT, Raza MW, Ogilvie MM, Weir DM, et al. The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. FEMS Immunol Med Microbiol. 1999;23:27–36.CrossRefPubMed
Metadata
Title
Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study
Authors
Péter Torzsa
Raghavendra Devadiga
Monica Tafalla
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2356-2

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue